# Enquyst Technologies

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/enquyst-technologies

- Industry: Biotechnology
- Headquarters: Lowell, US
- Website: enquyst.com/
- Total disclosed funding: $6M
- Latest round: Series B (Jun 4, 2025)
- Investors on record: 2

## About

Based in Massachusetts, US, and founded in 2017, Enquyst Technologies Inc, formerly known as Mobius Biomedical Inc. is a biologics manufacturing technology developer that primarily assists the biopharmaceutical industry in saving money and time. In March 2022, Enquyst Technologies Inc raised an undisclosed amount of venture funding from Eckuity and Forepont Capital Partners. As of 2022, Vishal Jain is the Interim CEO of the company. The company is developing next-generation continuous biologics manufacturing technologies to bring unprecedented efficiencies in cost, time, footprint, and speed to market at the commercial scale for monoclonal antibody and gene therapy production. The firm’s technology reduces facility footprint, setup time, and cost, and provides the flexibility to manufacture biological drug products, as its flexible equipment modules are designed to enable continuous manufacturing of protein-therapeutics, RNA-therapeutics, and gene therapies. The organization plans to use the March 2022 investment to further expand its team and accelerate development.

## Funding rounds

- Series B, Jun 4, 2025, $6M — New Jersey Economic Development Authority, Eckuity Capital

## Investors

- New Jersey Economic Development Authority — Series B
- Eckuity Capital (https://capitalatlas.ai/funds/eckuity-capital) — Series B